Phase 1 trial will assess the safety, pharmacokinetic and pharmacodynamic profile of BCX4161, a novel selective inhibitor of plasma kallikrein, in healthy volunteers. The study that is being
The research will focus on identifying and validating recurrent gene mutations that are potential targets for drug therapies. H3 Biomedicine president and CEO Markus Warmuth said genomic information
The multi-year research and development collaboration aims to apply gene therapy technology to modify a patient’s own T-cells genetically, known as chimeric antigen receptor (CAR) T-cells, to target
The larger facility located at 21 Finchdene Square, Toronto, increases the division’s footprint by 95,000ft² along with its capacity and capabilities. Bellwyck co-chief executive officer John Vella said,
CDI will receive $16m in funding to create three induced pluripotent stem cell (iPSC) lines for each of 3000 healthy and diseased donors, while Coriell Institute will get
Aubagio did not receive positive opinion from the committee concerning new active substance (NAS) designation. Genzyme CEO and president David Meeker said the positive CHMP opinion and broad
Simcere Pharmaceutical holds 52.5% equity interest in Simcere Vaxtec subsidiary that expects to resume influenza vaccine production. Separately, the company also announced the resignation of executive vice president
TOBI Podhaler is new non-nebulized formulation and delivery system of tobramycin that is indicated for CF patients with Pseudomonas aeruginosa (Pa) bacteria in the lungs. The first dry
Probuphine is a long-acting, subdermal implant formulation of buprenorphine for the maintenance treatment of adult patients with opioid dependence. Titan Pharmaceuticals executive vice president and chief development officer
The sanction involves the temporary suspension of Takeda’s activities as vice president of the JPMA for the period of six months starting from 21March 2013. In December 2012
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.